In vitrosynergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells

Introduction Bisphosphonates are mostly used in the treatment of bone metastases. They have been shown to act synergistically with other chemotherapeutic agents. It is not known, however, whether similar synergistic effects exist with radiation on breast cancer cells. Methods Human MCF-7 breast canc...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research : BCR 2006-08, Vol.8 (4), Article R52
Main Authors: Ural, A Ugur, Avcu, Ferit, Candir, Muhammed, Guden, Metin, Ozcan, M Ali
Format: Article
Language:English
Subjects:
Analysis
Breast cancer
Cancer
Cancer cells
Chemotherapy
Metastasis
Radiation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Bisphosphonates are mostly used in the treatment of bone metastases. They have been shown to act synergistically with other chemotherapeutic agents. It is not known, however, whether similar synergistic effects exist with radiation on breast cancer cells. Methods Human MCF-7 breast cancer cells were treated with up to 100 [mu]M zoledronic acid, were irradiated with up to 800 cGy or were exposed to combinations of both treatments to determine the antiproliferative effects of zoledronic acid and radiation. Results Zoledronic acid and radiation caused a dose-dependent and time-dependent decrease in cell viability (approximate 50% growth inhibition values were 48 [mu]M and 20 [mu]M for 24 hours and 72 hours, respectively, for zoledronic acid and 500 cGy for radiation). A synergistic cytotoxic effect of the combination of zoledronic acid and radiation was confirmed by isobologram analysis. Conclusion These data constitute the first in vitro evidence for synergistic effects between zoledronic acid and radiation. This combination therapy might thus be expected to be more effective than either treatment alone in patients with metastatic breast carcinoma.
ISSN:1465-542X
1465-5411
1465-542X
DOI:10.1186/bcr1543